MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 Zug, Switzerland, April 25, 2025 - MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company ...

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 ...

Akeso Inc. scored U.S. FDA approval of the PD-1 monoclonal antibody penpulimab in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or ...

Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...